Saudi Arabia – Strategic Planning Consultancy Opportunity

2nd February 2018

MSIF is seeking experienced consultant(s) or a Consultancy Company based in Saudi Arabia to provide mentoring and…

Join our team – Campaign Support Officer

31st January 2018

We are looking for a strong communicator to support the World MS Day team at our friendly…

Healthy diet linked to lower disability in people with MS

26th January 2018

New study shows eating a diet high in whole grains, fruit, vegetables and legumes may lead to…

Cyprus Multiple Sclerosis Association translates Quality of Life principles into Greek

25th January 2018

MSIF’s ‘Seven principles to improve quality of life with MS’, already available in English, Spanish, Arabic, and…

Refining diagnosis for people with MS

25th January 2018

Expert panel publishes revised criteria for MS diagnosis

The eyes as possible windows into MS

24th January 2018

Two recent scientific publications add further evidence that a simple eye test may offer a fast and…

Singer with MS and young supporters of Japan MS Society perform at school concert

24th January 2018

Singer Keiko joined young supporters of the Japan MS Society for a festive, awareness-raising event at an…

Union Roska holds first sports games for people with MS

24th January 2018

Czech MS organisation Union Roska marked its 25th anniversary with the Roskiáda Sports Games, a new sports…

People with MS who have additional health conditions are more likely to experience relapses

23rd January 2018

Canadian study finds people with MS who have additional health conditions face a greater risk of having…

Argentina presents awards to MS researchers

23rd January 2018

The Association for the Fight Against MS (ALCEM) presents the Miguel Pablo Gallardo award and the Proyecto…

Tawasol – Dec 2017 issue

15th January 2018

Latest news from 17 organisations in the Arab region

First treatment for early primary progressive MS approved in Europe

12th January 2018

The European Commission has approved the first disease-modifying therapy, ocrelizumab, for early primary progressive MS (PPMS).